2. Academic Validation
  3. Verification of fasting-mimicking diet to assist monotherapy of human cancer-bearing models

Verification of fasting-mimicking diet to assist monotherapy of human cancer-bearing models

  • Biochem Pharmacol. 2023 Jul 21;115699. doi: 10.1016/j.bcp.2023.115699.
Wenping Huang 1,  Xiaoyang Li 2,  Haohao Song 3,  Yue Yin 4,  Hai Wang 5
Affiliations

Affiliations

  • 1 CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  • 2 Department of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • 3 CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
  • 4 CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China; School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China. Electronic address: yinyue@bit.edu.cn.
  • 5 CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: wanghai@nanoctr.cn.
PMID: 37482198 DOI: 10.1016/j.bcp.2023.115699
Abstract

The efficacy of a single clinical nanodrug for Cancer treatment is still unsatisfactory, especially for drug-resistant Cancer. Herein, we applied a fasting-mimicking diet (FMD) approach via dietary intervention to assist single clinical nanodrug for breast or ovarian Cancer treatments instead of using multi-drug therapies which might cause adverse side effects. Specifically, we adopted Doxil or Abraxane to treat human breast tumor-bearing nude mice and Doxil to treat the human ovarian tumor and drug-resistant ovarian tumor-bearing nude mice under FMD conditions, respectively. According to the results, the FMD condition can promote the cellular uptake and cytotoxicity of a single nanodrug, reduce the ATP level in drug-resistant tumor cells to hinder drug efflux, normalize tumor blood vessels, relieve tumor hypoxia, and increase the accumulation of nanodrugs at tumor sites, thereby enhancing the therapeutic effects on these types of human cancers. Collectively, these results demonstrate that the FMD strategy of significance can become a practical, alternative, and promising assistant for single nanodrug for enhancing Cancer therapy and clinical translation.

Keywords

Abraxane; Cancer; Doxil; Drug-resistance; Fasting-mimicking diet (FMD).

Figures
Products